NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) is a publicly traded clinical-stage life sciences company focused on the development and commercialization of central nervous system therapeutics designed to overcome the blood-brain barrier. The company’s NEO™ drug development platform has produced a portfolio of novel drug candidates and delivery methods with patent protections extending to 2038. NeOnc’s NEO100™-01 and NEO100™-02 therapeutics are in Phase II, and the NEO100™-03 and NEO212™ therapeutics are in Phase I clinical trials, advancing under FDA Fast-Track and Investigational New Drug (IND) status.
23975 Park Sorrento Suite 205
Calabasas, CA 91302
Delaware on January 5, 2023
The stock began trading on the Nasdaq Global Market under the symbol NTHI on March 26, 2025 through a registered direct offering.
The last day of the company’s fiscal year is December 31. Its fiscal quarters end on March 31, June 30, September 30, and December 31.
The CUSIP number for the Common Stock is 64051A101.
VStock Transfer
18 Lafayette Place
Woodmere, New York 11598
Tel (212) 828-8436
Toll-Free: 855-9VSTOCK
Contact the company’s transfer agent at (212) 828-8436 or submit your inquiry here.
CBiz CPAs
Manatt, Phelps & Phillips
695 Town Center Drive, 14th Floor
Costa Mesa, CA 92626
Tel (714) 371-2501
PondelWilkinson Inc., pwinvestor@pondel.com
Laurie Berman, lberman@pondel.com; 310-279-5962
Roger Pondel, rpondel@pondel.com; 310-279-5965
PondelWilkinson Inc., pwinvestor@pondel.com
Laurie Berman, lberman@pondel.com; 310-279-5962
Roger Pondel, rpondel@pondel.com; 310-279-5965
Email the Company through the contact page or subscribe to our email alerts here.